

or animal body or cellular extracts thereof, in particular from thymus, lung, pancreas, cartilage, endothelium, neuromuscular junctions, prostate, sexual organs, bladder, muscles, peripheral nerves, CNS extracts, spleen, liver, bone, heart, skin cells.

Amend claim 8 as follows:

--8. (amended) Molecular complex according to claim 1, wherein the monocyte derived cells recognized by said molecular complex are macrophages, dendritic cells, or antigen presenting cells.

Amend claim 9 as follows:

--9. (amended) Monocyte derived cells such as prepared according to a process comprising the step of contacting monocyte derived cells with a molecular complex according to claim 1.

Amend claim 10 as follows:

--10. (amended) Monocyte derived cells such as prepared according to a process comprising contacting monocyte derived cells with a molecular complex according to claim 1, under conditions enabling phagocytosis of said molecular complex by said monocyte derived cells, intracellular degradation and processing of the known and unknown components of the tumor tissue extract and the presentation of said known and unknown components on the peripheral membrane of the monocyte derived cells together with MHC I and MHC II molecules.

Amend claim 11 as follows:

Jacques BARTHOLEYNS et al.

--11. (amended) Monocyte derived cells such as prepared according to a process comprising contacting monocyte derived cells with a molecular complex according to claim 1, under conditions enabling phagocytosis of such molecular complex by the monocyte derived cells.

Amend claim 12 as follows:

--12. (amended) *Ex vivo* method for stimulating cellular and/or humoral immune responses against unknown components of a tumor tissue extract comprising contacting monocyte derived cells with a molecular complex according to claim 1, under conditions enabling phagocytosis of said molecular complex by monocyte derived cells, intracellular degradation and processing of the known and of unknown components of the tumor tissue extract and the presentation of said known and unknown components on the peripheral membrane of the monocyte derived cells, together with MHC I and II molecules.

Amend claim 13 as follows:

--13. (amended) Method of inducing *in vivo* specific cellular and/or humoral immune responses against unknown components of tumor tissue extract comprising injections of a molecular complex according to claim 1, for instance by intramuscular, subcutaneous, local or intravenous route.

Amend claim 14 as follows:

--14. (amended) Method of inducing *in vivo* specific cellular and/or humoral responses against unknown components of a tumor tissue extract, comprising sequential and/or

Jacques BARTHOLEYNS et al.

simultaneous injections of monocyte derived cells presenting known and unknown components of said tumor tissue extract, together with MHC I and II molecules, as defined in claim 12, and of molecular complexes.

Amend claim 15 as follows:

--15. (amended) Method for conditioning ex vivo human monocytes derived cells, and preferentially macrophages, for them to acquire tissue specificity, comprising contacting monocyte derived cells with a molecular complex according to claim 1, under conditions enabling phagocytosis of such molecular complex by the monocyte derived cells.

Amend claim 16 as follows:

--16. (amended) Method of treatment of diseases involving accumulation of conditioned monocyte derived cells according to claim 15 in specific tissue to induce tissue repair and/or regeneration comprising:

- either simultaneous and/or sequential injections of monocyte derived cells and of a molecular complex under conditions enabling phagocytosis,
- or injection of the monocyte derived cells which have previously phagocytosed a molecular complex.

R E M A R K S

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The